Trump's Tylenol claims limit M&A options for parent company Kenvue

Core Viewpoint - Kenvue, the maker of Tylenol, has been experiencing significant challenges in the current year, exacerbated by involvement from U.S. President Donald Trump and his health secretary [1] Company Summary - Kenvue is facing a difficult year, indicating potential operational and financial struggles [1] Industry Summary - The involvement of high-profile political figures such as the U.S. President and health secretary suggests that external factors may be influencing the pharmaceutical industry, particularly in relation to product perception and regulatory scrutiny [1]